American Vietnamese Biotech Incorporation (HNX:AMV)
Vietnam
· Delayed Price · Currency is VND 1,700.00
-100.00 (-5.56%)
At close: Apr 28, 2026
HNX:AMV Revenue
In the year 2025, American Vietnamese Biotech Incorporation had annual revenue of 154.07B VND, down -50.36%. American Vietnamese Biotech Incorporation had revenue of 39.52B in the quarter ending December 31, 2025, a decrease of -82.30%.
Revenue
154.07B
Revenue Growth
-50.36%
P/S Ratio
1.45
Revenue / Employee
1.50B
Employees
103
Market Cap
222.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 154.07B | -156.29B | -50.36% |
| Dec 31, 2024 | 310.35B | 113.78B | 57.88% |
| Dec 31, 2023 | 196.57B | -85.25B | -30.25% |
| Dec 31, 2022 | 281.82B | 57.98B | 25.90% |
| Dec 31, 2021 | 223.84B | 62.41B | 38.66% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2010 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vimedimex Medi-Pharma JSC | 812.98B |
| Ben Tre Pharmaceutical JSC | 860.31B |
| Mediplantex National Pharmaceutical JSC | 366.83B |
| Phong Phu Pharmaceutical JSC | 139.74B |
| Lamdong Pharmaceutical JSC | 243.91B |
| SPM Corporation | 217.45B |
| Cai Lay Veterinary Pharmaceutical JSC | 152.40B |
| Vidipha Central Pharmaceutical JSC | 971.25B |